NCT00516152已完成2 期
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 2
研究概览
简要总结
The primary objective of this study is to assess the safety and efficacy of performing unrelated stem cell transplants using intravenous busulfan and fludarabine as preparative therapy and tacrolimus plus methotrexate as the GVHD prophylaxis regimen. The goal is to demonstrate safety, aiming for a transplant related mortality rate (TRM) of < or equal to 40% at 100 days. A TRM of > or equal to 60% will be considered unacceptable. Another goal is to demonstrate efficacy by showing and overall survival of >40% at 1-year following transplant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 61 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •No fully or single-antigen mismatched sibling donor is available to donate stem cells.
- •Age >15 and <61
- •ECOG PS < or equal to 2
- •Adequate renal function with serum creatinine <2.0 mg/dl
- •Pulmonary diffusing capacity >40% of predicted
- •Cardiac ejection fraction >40% as measured by radionuclide wall motion study or echocardiography
- •No active liver disease. Total bilirubin must be < or equal to 2.0 mg/dl. Alkaline phosphatase and AST must be less than three times the upper limit of normal. Patients with hepatitis C and active hepatitis B are eligible only if a liver biopsy is performed and there is < or equal to grade 2 inflammation. Patients wtih a history of HBV infection should be tested for HBeAg, antiHBe and HBV DNA (quantitative). Patients with active HBV viral replication should receive anti-viral therapy.
- •Negative serology for the human immunodeficiency virus (HIV)
- •Available HLA-matched donor (see HLA compatibility requirements below)
- •Signed informed consent from the recipient
排除标准
- •Ongoing active infection
- •Pregnancy and/or nursing
- •Active, uncontrolled CNS leukemia
- •Opinion of BMT Committee that autologous or mini-allogeneic transplant would be the preferable form of treatment
- •Receipt of any chemotherapy within 3 weeks of study entry except for hydroxyurea or imatinib mesylate. Use of interferon within 3 months of starting therapy.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningAcute Lymphocytic LeukemiaChronic Myeloid LeukemiaMyeloproliferative DiseasesNon-Hodgkins LymphomaLeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaHodgkins LymphomaMultiple MyelomaMyelodysplastic SyndromeNCT01572662M.D. Anderson Cancer Center201
已完成
2 期
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 YearsChronic Lymphocytic LeukemiaNCT00254410M.D. Anderson Cancer Center30
已完成
2 期
Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for MyelofibrosisMyelofibrosisNCT01814475Gruppo Italiano Trapianto di Midollo Osseo62
Unknown
4 期
Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell TransplantationLeukemiaNCT02784561Chinese PLA General Hospital80
已完成
2 期
Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan RegimenLeukemiaMyelodysplastic SyndromeNCT00852163Baylor Research Institute20